Hepatokines: Linking nonalcoholic fatty liver disease and insulin resistance

Nature Reviews Endocrinology

Volumn 13, Issue 9, 2017, Pages 509-520

  Meex, Ruth C R ^a,b   Watt, Matthew J ^a  

^a MONASH UNIVERSITY   (Australia)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN 4; CELL PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; FATTY ACID; FETUIN A; FETUIN B; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; HEPASSOCIN; HEPATOKINES; LIVER PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE C EPSILON; PROTEIN LECT2; RETINOL BINDING PROTEIN 4; SELENOPROTEIN P; SEX HORMONE BINDING PROTEIN; TRANSCRIPTION FACTOR FKHR; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; PLASMA PROTEIN; PLASMA RETINOL BINDING PROTEIN; RBP4 PROTEIN, HUMAN;

ENDOPLASMIC RETICULUM STRESS; FAT INTAKE; FATTY ACID OXIDATION; GLUCOSE BLOOD LEVEL; GLYCOLYSIS; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIPOLYSIS; LIPOTOXICITY; LIVER CELL; LIVER METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE PHOSPHORYLATION; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; ANIMAL; HYPERTRIGLYCERIDEMIA; LIPID DIET; LIVER; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALPHA-2-HS-GLYCOPROTEIN; ANIMALS; BLOOD PROTEINS; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; FETUIN-B; HUMANS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; OVERWEIGHT; RETINOL-BINDING PROTEINS, PLASMA; SELENOPROTEIN P;

EID: 85028589380     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2017.56     Document Type: Review

References (100)

1. Kleiner, D. E., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321 (2005).
2. Younossi, Z. M., et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73-84 (2016).
3. Browning, J. D., et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 40, 1387-1395 (2004).
4. Bellentani, S., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 132, 112-117 (2000).
5. Luyckx, F. H., et al. Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty. Int. J. Obes. Relat. Metab. Disord. 22, 222-226 (1998).
6. Silverman, J. F., et al. Liver pathology in morbidly obese patients with and without diabetes. Am. J. Gastroenterol. 85, 1349-1355 (1990).
7. Leite, N. C., Salles, G. F., Araujo, A. L., Villela-Nogueira, C. A. & Cardoso, C. R. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 29, 113-119 (2009).
8. Ludwig, J., Viggiano, T. R., McGill, D. B. & Oh, B. J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 55, 434-438 (1980).
9. Wicklow, B. A., et al. Metabolic consequences of hepatic steatosis in overweight and obese adolescents. Diabetes Care 35, 905-910 (2012).
10. Yoo, H. J. & Choi, K. M. Hepatokines as a link between obesity and cardiovascular diseases. Diabetes Metab. J. 39, 10-15 (2015).
11. Oni, E. T., et al. A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care Atherosclerosis 230, 258-267 (2013).
12. Ong, J. P., Pitts, A. & Younossi, Z. M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J. Hepatol. 49, 608-612 (2008).
13. Yang, S. J., et al. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: Implications for insulin resistance, inflammation, and atherosclerosis. J. Clin. Endocrinol. Metab. 96, E1325-E1329 (2011).
14. Michos, E. D., et al. Sex hormones, sex hormone binding globulin, and abdominal aortic calcification in women and men in the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis 200, 432-438 (2008).
15. Li, Q., et al. Association between serum fibroblast growth factor 21 and mortality among patients with coronary artery disease. J. Clin. Endocrinol. Metab. 101, 4886-4894 (2016).
16. Zhao, L. P., et al. Serum adropin level in patients with stable coronary artery disease. Heart Lung Circ. 24, 975-979 (2015).
17. Ng, M., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 384, 766-781 (2014).
18. Donnelly, K. L., et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115, 1343-1351 (2005).
19. Arner, P. & Langin, D. Lipolysis in lipid turnover, cancer cachexia, and obesity-induced insulin resistance. Trends Endocrinol. Metab. 25, 255-262 (2014).
20. Del Prato, S., et al. Insulin regulation of glucose and lipid metabolism in massive obesity. Diabetologia 33, 228-236 (1990).
21. Fabbrini, E., et al. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 134, 424-431 (2008).
22. Choi, Y. H., et al. Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B-null mice. J. Clin. Invest. 116, 3240-3251 (2006).
23. Pagnon, J., et al. Identification and functional characterization of protein kinase A phosphorylation sites in the major lipolytic protein, adipose triglyceride lipase. Endocrinology 153, 4278-4289 (2012).
24. Chakrabarti, P. & Kandror, K. V. FoxO1 controls insulin-dependent adipose triglyceride lipase (ATGL) expression and lipolysis in adipocytes. J. Biol. Chem. 284, 13296-13300 (2009).
25. Lindeboom, L., et al. Proton magnetic resonance spectroscopy reveals increased hepatic lipid content after a single high-fat meal with no additional modulation by added protein. Am. J. Clin. Nutr. 101, 65-71 (2015).
26. Turner, N., et al. Distinct patterns of tissue-specific lipid accumulation during the induction of insulin resistance in mice by high-fat feeding. Diabetologia 56, 1638-1648 (2013).
27. van Herpen, N. A., Schrauwen-Hinderling, V. B., Schaart, G., Mensink, R. P. & Schrauwen, P. Three weeks on a high-fat diet increases intrahepatic lipid accumulation and decreases metabolic flexibility in healthy overweight men. J. Clin. Endocrinol. Metab. 96, E691-E695 (2011).
28. Madry, K., Lut, W., Lepert, R., Borkowska, M. & Papiernik, E. Lipid composition of plasma obtained from various parts of the vascular system of the rabbit. Acta Physiol. Pol. 27, 485-492 (1976).
29. Lindeboom, L., et al. Quantum coherence spectroscopy to measure dietary fat retention in the liver. JCI Insight 1, e84671 (2016).
30. Cohen, J. C., Horton, J. D. & Hobbs, H. H. Human fatty liver disease: Old questions and new insights. Science 332, 1519-1523 (2011).
31. Hellerstein, M. K., Schwarz, J. M. & Neese, R. A. Regulation of hepatic de novo lipogenesis in humans. Annu. Rev. Nutr. 16, 523-557 (1996).
32. Ameer, F., Scandiuzzi, L., Hasnain, S., Kalbacher, H. & Zaidi, N. De novo lipogenesis in health and disease. Metabolism 63, 895-902 (2014).
33. Horton, J. D., Goldstein, J. L. & Brown, M. S. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125-1131 (2002).
34. Uyeda, K., Yamashita, H. & Kawaguchi, T. Carbohydrate responsive element-binding protein (ChREBP): A key regulator of glucose metabolism and fat storage. Biochem. Pharmacol. 63, 2075-2080 (2002).
35. Timlin, M. T. & Parks, E. J. Temporal pattern of de novo lipogenesis in the postprandial state in healthy men. Am. J. Clin. Nutr. 81, 35-42 (2005).
36. Degli Esposti, D., et al. Mitochondrial roles and cytoprotection in chronic liver injury. Biochem. Res. Int. 2012, 387626 (2012).
37. Rector, R. S., et al. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J. Hepatol. 52, 727-736 (2010).
38. Szendroedi, J., et al. Abnormal hepatic energy homeostasis in type 2 diabetes. Hepatology 50, 1079-1086 (2009).
39. Ibdah, J. A., et al. Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. Gastroenterology 128, 1381-1390 (2005).
40. Kim, C. S., et al. Quercetin reduces obesity-induced hepatosteatosis by enhancing mitochondrial oxidative metabolism via heme oxygenase-1. Nutr. Metab. (Lond.) 12, 33 (2015).
41. Aasum, E., et al. Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice. J. Mol. Cell. Cardiol. 44, 201-209 (2008).
42. Park, H. S., et al. Statins increase mitochondrial and peroxisomal fatty acid oxidation in the liver and prevent non-alcoholic steatohepatitis in mice. Diabetes Metab. J. 40, 376-385 (2016).
43. Demeilliers, C., et al. Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. Gastroenterology 123, 1278-1290 (2002).
44. Buchner, D. A., et al. Increased mitochondrial oxidative phosphorylation in the liver is associated with obesity and insulin resistance. Obesity (Silver Spring) 19, 917-924 (2011).
45. Koliaki, C., et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 21, 739-746 (2015).
46. Sunny, N. E., Parks, E. J., Browning, J. D. & Burgess, S. C. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab. 14, 804-810 (2011).
47. Dongiovanni, P. & Valenti, L. Genetics of nonalcoholic fatty liver disease. Metabolism 65, 1026-1037 (2016).
48. Hussain, M. M., Shi, J. & Dreizen, P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J. Lipid Res. 44, 22-32 (2003).
49. Chen, Z., Fitzgerald, R. L., Averna, M. R. & Schonfeld, G. A targeted apolipoprotein B-38.9-producing mutation causes fatty livers in mice due to the reduced ability of apolipoprotein B-38.9 to transport triglycerides. J. Biol. Chem. 275, 32807-32815 (2000).
50. Cefalu, A. B., et al. A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia. Arterioscler. Thromb. Vasc. Biol. 33, 2021-2025 (2013).
51. Hsiao, P. J., et al. MTTP-297H polymorphism reduced serum cholesterol but increased risk of non-alcoholic fatty liver disease-a cross-sectional study. BMC Med. Genet. 16, 93 (2015).
52. Targher, G., et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54, 3541-3546 (2005).
53. Ducluzeau, P. H., et al. MRI measurement of liver fat content predicts the metabolic syndrome. Diabetes Metab. 39, 314-321 (2013).
54. Kotronen, A., et al. Fatty liver score and 15-year incidence of type 2 diabetes. Hepatol. Int. 7, 610-621 (2013).
55. Park, S. K., Seo, M. H., Shin, H. C. & Ryoo, J. H. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology 57, 1378-1383 (2013).
56. Zelber-Sagi, S., et al. Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver Int. 33, 1406-1412 (2013).
57. Liu, L., Yin, X. & Morrissey, S. Global variability in diabetes mellitus and its association with body weight and primary healthcare support in 49 low-A nd middle-income developing countries. Diabet. Med. 29, 995-1002 (2012).
58. Virkamaki, A., et al. Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle. Diabetes 50, 2337-2343 (2001).
59. Krssak, M., et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: A 1H NMR spectroscopy study. Diabetologia 42, 113-116 (1999).
60. Jacob, S., et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 48, 1113-1119 (1999).
61. Goodpaster, B. H., Thaete, F. L., Simoneau, J. A. & Kelley, D. E. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 46, 1579-1585 (1997).
62. Kelley, D. E., Thaete, F. L., Troost, F., Huwe, T. & Goodpaster, B. H. Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 278, E941-E948 (2000).
63. Unger, R. H. Minireview: Weapons of lean body mass destruction: The role of ectopic lipids in the metabolic syndrome. Endocrinology 144, 5159-5165 (2003).
64. Fabbrini, E., et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc. Natl Acad. Sci. USA 106, 15430-15435 (2009).
65. Korenblat, K. M., Fabbrini, E., Mohammed, B. S. & Klein, S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 134, 1369-1375 (2008).
66. D'Adamo, E., et al. Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents. Diabetes Care 33, 1817-1822 (2010).
67. Linder, K., et al. Relationships of body composition and liver fat content with insulin resistance in obesity-matched adolescents and adults. Obesity (Silver Spring) 22, 1325-1331 (2014).
68. Gastaldelli, A., et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 133, 496-506 (2007).
69. Koska, J., et al. Increased fat accumulation in liver may link insulin resistance with subcutaneous abdominal adipocyte enlargement, visceral adiposity, and hypoadiponectinemia in obese individuals. Am. J. Clin. Nutr. 87, 295-302 (2008).
70. Stefan, N., et al. Identification and characterization of metabolically benign obesity in humans. Arch. Intern. Med. 168, 1609-1616 (2008).
71. Zhang, H., et al. Hepatic fat content is a determinant of metabolic phenotypes and increased carotid intima-media thickness in obese adults. Sci. Rep. 6, 21894 (2016).
72. Halaas, J. L., et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269, 543-546 (1995).
73. Shimomura, I., et al. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell 6, 77-86 (2000).
74. Oakes, N. D., Cooney, G. J., Camilleri, S., Chisholm, D. J. & Kraegen, E. W. Mechanisms of liver and muscle insulin resistance induced by chronic high-fat feeding. Diabetes 46, 1768-1774 (1997).
75. Samuel, V. T., et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 279, 32345-32353 (2004).
76. Kraegen, E. W., et al. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 40, 1397-1403 (1991).
77. Davis, R. C., et al. Early hepatic insulin resistance precedes the onset of diabetes in obese C57BLKS-db/db mice. Diabetes 59, 1616-1625 (2010).
78. Kim, J. K., et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc. Natl Acad. Sci. USA 98, 7522-7527 (2001).
79. Linden, D., et al. Liver-directed overexpression of mitochondrial glycerol-3-phosphate acyltransferase results in hepatic steatosis, increased triacylglycerol secretion and reduced fatty acid oxidation. FASEB J. 20, 434-443 (2006).
80. Neschen, S., et al. Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice. Cell Metab. 2, 55-65 (2005).
81. An, J., et al. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat. Med. 10, 268-274 (2004).
82. Turpin, S. M., et al. Adipose triacylglycerol lipase is a major regulator of hepatic lipid metabolism but not insulin sensitivity in mice. Diabetologia 54, 146-156 (2011).
83. Savage, D. B., et al. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J. Clin. Invest. 116, 817-824 (2006).
84. Choi, C. S., et al. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J. Biol. Chem. 282, 22678-22688 (2007).
85. Monetti, M., et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab. 6, 69-78 (2007).
86. Wu, J. W., et al. Deficiency of liver adipose triglyceride lipase in mice causes progressive hepatic steatosis. Hepatology 54, 122-132 (2011).
87. Jacobs, R. L., et al. Impaired de novo choline synthesis explains why phosphatidylethanolamine N-methyltransferase-deficient mice are protected from diet-induced obesity. J. Biol. Chem. 285, 22403-22413 (2010).
88. Sun, Z. & Lazar, M. A. Dissociating fatty liver and diabetes. Trends Endocrinol. Metab. 24, 4-12 (2013).
89. Nagle, C. A., Klett, E. L. & Coleman, R. A. Hepatic triacylglycerol accumulation and insulin resistance. J. Lipid Res. 50 (Suppl.), S74-S79 (2009).
90. Seppala-Lindroos, A., et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol. Metab. 87, 3023-3028 (2002).
91. Utzschneider, K. M. & Kahn, S. E. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 91, 4753-4761 (2006).
92. Perry, R. J., Samuel, V. T., Petersen, K. F. & Shulman, G. I. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510, 84-91 (2014).
93. Puri, P., et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46, 1081-1090 (2007).
94. Kumashiro, N., et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc. Natl Acad. Sci. USA 108, 16381-16385 (2011).
95. Magkos, F., et al. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology 142, 1444-1446.e2 (2012).
96. Chaurasia, B. & Summers, S. A. Ceramides-lipotoxic inducers of metabolic disorders. Trends Endocrinol. Metab. 26, 538-550 (2015).
97. Lackey, D. E. & Olefsky, J. M. Regulation of metabolism by the innate immune system. Nat. Rev. Endocrinol. 12, 15-28 (2016).
98. Ozcan, U., et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 457-461 (2004).
99. Ozcan, U., et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313, 1137-1140 (2006).
100. Howarth, D. L., et al. Alcohol disrupts endoplasmic reticulum function and protein secretion in hepatocytes. Alcohol Clin. Exp. Res. 36, 14-23 (2012).